Abstract

Objective: To invetigate the influencing factors and clinical significance of liver function damage (LFD) in patients diagnosed with Corona Virus Disease 2019 (COVID-19) Methods: The retrospective case-control study was conducted The clinicopathological data of 51 patients with COVID-19 who were admitted to the Sino-French New City Branch of Tongji Hospital Affiliated to Huazhong University of Science and Technology by the 5th group assisting team from the First Hospital of Jilin University from February 9th to 27th in 2020 were collected There were 27 males and 24 females, aged from 36 to 86 years, with an average age of 68 years The treatment modality was according to the diagnostic and therapeutic guideline for COVID-19 (Trial 6th edition) issued by National Health Commission Observation indicators: (1) clinical data of patients;(2) analysis of liver function index and treatment of LFD;(3) analysis of influencing factors for LFD Measurement data with normal distribution were represented as Mean±SD, and measurement data with skewed distribution were described as M (range) Count data were described as absolute numbers or percentages, and comparison between groups was analyzed using the chi-square test The Logistic regression method was used for univariate analysis Results: (1) Clinical data of patients: of the 51 patients, 21 were classified as ordinary type of COVID-19, 19 as severe type and 11 as critical type In terms of medical history, 31 patients suffered from more than or equal to one kind of chronic disease, 20 had no history of chronic disease Thirteen patients had the drinking history and 38 had no drinking history Seven patients were hepatitis positive and 44 were hepatitis negative Five patients had septic shock at admission, 5 had systemic inflammatory response syndrome (SIRS), and 41 had neither shock nor SIRS The body mass index (BMI), time from onset to admission, temperature, heart rate, respiratory rate of the 51 patients were (24±3)kg/m2, (13±5)days, 36 5 ℃ (range, 36 0-38 1 ℃), 82 times/minutes (range, 50-133 times/minutes), 20 times/minutes (range, 12-40 times/minutes) The white blood cell count, level of creatinine, and level of b-type natriuretic peptide within 24 hours after admission were 6 3×109/L [range, (2 2-21 7)×109/L], 75 μmol/L (range, 44-342 μmol/L), 214 ng/L (range, 5-32 407 ng/L) (2) Analysis of liver function index and treatment of LFD: the level of alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), direct bilirubin (DBil), indirect bilirubin (IBil), activated partial thromboplastin time (APTT) and prothrombin time (PT) were 31 U/L (range, 7-421 U/L), 29 U/L (range, 15-783 U/L), 36 U/L (range, 13-936 U/L), 76 U/L (range, 41-321 U/L), 4 9 μmol/L (range, 2 6-14 3 μmol/L), 5 8 μmol/L (range, 2 6-23 9 μmol/L), 37 2 s (range, 30 9-77 1 s), 13 9 s (range, 12 5-26 7 s), respectively The percentages of cases with abnormal ALT, AST, GGT, ALP, DBil, IBil, APTT and PT were 47 1%(24/51), 47 1%(24/51), 35 3%(18/51), 13 7%(7/51), 7 8%(4/51), 2 0%(1/51), 21 6%(11/51), and 19 6%(10/51), respectively Of the 51 patients, LFD was detected in 10 patients classified as ordinary type, in 9 patients as severe type, and in 10 as critical type, respectively In the 51 patients, 1 of 22 patients with normal liver function developed respiratory failure and received mechanical ventilation within 24 hours after admission, while 9 of 29 patients with abnormal liver function developed respiratory failure and received mechanical ventilation, showing a significant difference between the two groups (χ2=5 57, P<0 05) (3) Analysis of influencing factors for LFD Results of univariate analysis showed that clinical classification of COVID-19 as critical type was a related factor for LFD of patients (odds ratio=10 000, 95% confidence interval: 1 050-95 231, P<0 05) Conclusions: COVID-19 patients with LFD are more susceptible to develop respiratory failure The clinical classification of COVID-19 as cr tical type is a related factor for LFD of patients Copyright © 2020 by the Chinese Medical Association

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.